Immunomedics Inc. said Thursday that its new cancertherapeutic induced the regression of lymphomas in mice.

Data on the antibody toxin conjugate were presented at theAmerican Association for Cancer Research meeting in San Diego.

The drug consists of Pseudomonas exotoxin attached to thecompany's ImmuRAID-LL2. ImmuRAID-LL2 is a monoclonalantibody fragment specific for B-cell lymphoma tumors that islabeled with technetium-99.

The toxin selectively destroyed cancer cells growing in micewith minimal damage to normal cells, said Ira Pastan, chief ofmolecular biology at the National Cancer Institute and co-investigator on the collaborative research project. The Warren,N.J., company and the NCI are discussing the next step in thestudies, said Amy Factor, vice president of finance.

The company's shares (NASDAQ:IMMU) rose 13 cents to $7.88.

(c) 1997 American Health Consultants. All rights reserved.